Donepezil achieves modest cognitive benefit across mild-to-severe disease stages through reversible acetylcholinesterase inhibition, enhancing cholinergic neurotransmission, compensating for the basal forebrain cholinergic neuron degeneration characteristic of Alzheimer’s disease progression [43]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.